Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Kalaris Therapeutics Inc. (NASDAQ:KLRS) has earned an average rating of “Moderate Buy” from the six research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $14.00.

Several analysts have commented on the company. Wall Street Zen upgraded Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Chardan Capital assumed coverage on Kalaris Therapeutics in a research report on Tuesday, December 23rd. They set a “buy” rating and a $19.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kalaris Therapeutics in a report on Monday, December 29th. Finally, Citigroup reissued an “outperform” rating on shares of Kalaris Therapeutics in a research report on Thursday, December 18th.

Kalaris Therapeutics Stock Performance

Shares of Kalaris Therapeutics stock opened at $5.93 on Thursday. The company has a 50-day simple moving average of $8.78 and a two-hundred day simple moving average of $7.40. The stock has a market capitalization of $135.97 million, a PE ratio of -1.41 and a beta of 0.18. Kalaris Therapeutics has a 52-week low of $2.14 and a 52-week high of $11.88.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its quarterly earnings results on Tuesday, March 17th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.12.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. RTW Investments LP purchased a new stake in Kalaris Therapeutics in the fourth quarter worth approximately $10,972,000. Paradigm Biocapital Advisors LP bought a new position in shares of Kalaris Therapeutics during the 4th quarter valued at $5,908,000. Alyeska Investment Group L.P. bought a new position in shares of Kalaris Therapeutics during the 4th quarter valued at $3,402,000. Ikarian Capital LLC purchased a new position in shares of Kalaris Therapeutics in the 4th quarter worth $3,038,000. Finally, Woodline Partners LP purchased a new position in shares of Kalaris Therapeutics in the 3rd quarter worth $1,394,000. Institutional investors own 66.05% of the company’s stock.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.